Phenazine

Phenazine

SCHEMBL1226523

CCOS(=O)(=O)O.c1ccc2nc3ccccc3nc2c1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 3/20 0.41
GLA P06280 1/20 0.41
LMNA P02545 2/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
RXFP1 Q9HBX9 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
NQO2 P16083 2/20 0.38
CYP2C9 P11712 1/20 0.38
HIF1A Q16665 1/20 0.38
TOP2A P11388 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenazine SCHEMBL9174820 1.00 POLB (0.42) POLBMAPTKDM4EGLALMNA
SCHEMBL10674809 0.86 ALDH1A1 (0.43) POLBMAPTKDM4ELMNAHSD17B10
SCHEMBL31578887 0.84 NQO2 (0.65) POLBMAPTKDM4ELMNAMEN1
Phenazine SCHEMBL28658053 0.83 MAPT (0.55) POLBMAPTKDM4ELMNAMEN1
Quinoline SCHEMBL28332577 0.83 ALDH1A1 (0.53) MAPTKDM4ELMNAHSD17B10MEN1
Phenazine SCHEMBL8936740 0.82 NQO2 (0.61) POLBMAPTKDM4ELMNAMEN1
SCHEMBL8585681 0.81 NQO2 (0.46) POLBMAPTKDM4ELMNAMEN1
SCHEMBL8585680 0.81 NQO2 (0.48) POLBMAPTKDM4EGLALMNA
Catechol SCHEMBL23541091 0.80 CA2 (0.42) POLBMAPTKDM4ELMNAHSD17B10
Phenazine SCHEMBL2873102 0.79 MAPT (0.50) POLBMAPTKDM4ELMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450585-B Sensor for evaluating target analytes in liquid beverage samples 通用生物传感私人有限公司 2025-02-14 CN claimed
CN-117942073-A Enzyme mediator functionalized polymers for use with analyte sensors 美敦力迷你迈德公司 2024-04-30 CN claimed
CN-116249904-A Method for determining the amount of NAD metabolite from a sample and methods and uses related thereto 赫尔辛基大学 2023-06-09 CN claimed
CN-113652464-B Method for semi-synthesizing mogroside V through enzyme catalysis 湖南华诚生物资源股份有限公司 2023-01-24 CN claimed
EP-3774025-A1 SYSTEM, METHOD AND INTERFACE FOR PARALLEL PROCESSING OF ANTIMICROBIAL SUSCEPTIBILITY TESTS USING DIFFERENT SAMPLES Selux Diagnostics, Inc. (US) 2021-02-17 EP claimed
US-20200155125-A1 ORAL SAMPLING APPARATUS AND USES THEREOF THE PROCTER & GAMBLE COMPANY 2020-05-21 US claimed
US-20200149086-A1 METHODS FOR IMPROVED RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING SeLux Diagnostics, Inc. 2020-05-14 US claimed
EP-3638127-A1 ORAL SAMPLING APPARATUS AND USES THEREOF The Procter and Gamble Company (US) 2020-04-22 EP claimed
EP-3559252-A1 METHODS FOR IMPROVED RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING Selux Diagnostics, Inc. (US) 2019-10-30 EP claimed
WO-2019191328-A1 SYSTEM, METHOD AND INTERFACE FOR PARALLEL PROCESSING OF ANTIMICROBIAL SUSCEPTIBILITY TESTS USING DIFFERENT SAMPLES SeLux Diagnostics, Inc. (US) 2019-10-03 WO claimed
US-20160108391-A1 REAGENT COMPOSITIONS HAVING PYRIDINE-CARBOXYLIC ACID-STABILIZED ENZYMES, AS WELL AS METHODS OF MAKING AND USING THE SAME ROCHE DIABETES CARE, INC. (US) 2016-04-21 US claimed
EP-2994536-A1 STABILIZATION OF ENZYMES BY NICOTINIC ACID Roche Diagnostics GmbH (DE) 2016-03-16 EP claimed
EP-2823052-A1 COMPATIBLE SOLUTE ECTOINE AS WELL AS DERIVATIVES THEREOF FOR ENZYME STABILIZATION Roche Diagnostics GmbH (DE) 2015-01-14 EP claimed
US-20140363835-A1 COMPATIBLE SOLUTE ECTOINE AS WELL AS DERIVATIVES THEREOF FOR ENZYME STABILIZATION ROCHE DIABETES CARE, INC. 2014-12-11 US claimed
WO-2013131885-A1 COMPATIBLE SOLUTE ECTOINE AS WELL AS DERIVATIVES THEREOF FOR ENZYME STABILIZATION ROCHE DIAGNOSTICS GMBH (DE) 2013-09-12 WO claimed
EP-2636750-A1 Compatible solute ectoine as well as derivatives thereof for enzyme stabilization Roche Diagniostics GmbH (DE) 2013-09-11 EP claimed
US-7175430-B1 Support materials and imaging method for intraoral diagnostic purposes 3M ESPE AG (DE) 2007-02-13 US claimed
US-5196314-A Colorimetric, tetrazole compunds to reduce interference BOEHRINGER MANNHEIM GMBH (DE) 1993-03-23 US claimed
EP-0239931-B1 PROCESS AND REAGENT FOR THE DETERMINATION OF SUBSTRATES OR ENZYME ACTIVITIES Roche Diagnostics GmbH (DE) 1992-03-18 EP claimed
US-5013647-A Determination of enzyme substrate or enzyme activity, uric acid, creatinine BOEHRINGER MANNHEIM GMBH (DE) 1991-05-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200149086-A1 METHODS FOR IMPROVED RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING AMPD3, AMPD1, AMPD2 POLB 154/4885MAPT 4649/4885KDM4E 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.